Skip to main content
. Author manuscript; available in PMC: 2016 Jan 1.
Published in final edited form as: Exp Cell Res. 2014 Oct 16;330(1):199–211. doi: 10.1016/j.yexcr.2014.10.003

Fig. 4. Expression of M-CSFR, a molecular marker of macrophage differentiation, at protein level.

Fig. 4

AML cells were pretreated with either MEK1/2 inhibitors, PD98059 (20 µM) and U0126 (1 µM) or MEK5/ERK5 inhibitors, BIX02189 (10 µM) and XMD8-92 (5 µM), for 1 h, then 1,25D (1 nM) was added for an additional 96 h. TPA (10 nM) treated cells were used as the positive control. (A) M-CSFR (also known as CD115) total protein levels as determined by Western blotting. Normalized optical densities of each band are shown in the bar charts. Crk-L was used as a loading control. The blots shown are representative of three experiments. CTL = Control. PD = PD98059, U0 = U0126, BIX = BIX02189, XMD = XMD8-92.

(B) Expression of surface M-CSFR (CD115) was determined by flow cytometry. ◆ = p<0.05, ◆◆ = p<0.01, significantly increased vs. control group; # = p<0.05, ## = p<0.01, significantly increased vs. 1,25D-treated group, n=3.